



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Jing Liu,
ljing_syy@163.com
Miaoquan He,
hmiaoquan_syy@163.com
Jisheng Wang,
wjisheng_syy@163.com

SPECIALTY SECTION

This article was submitted to
Pharmacoepidemiology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 21 October 2022

ACCEPTED 24 October 2022

PUBLISHED 09 November 2022

CITATION

Guo H, Wang B, Yuan S, Wu S, Liu J,
He M and Wang J (2022), Corrigendum:
Neurological adverse events associated
with esketamine: A disproportionality
analysis for signal detection leveraging
the FDA adverse event reporting system.
Front. Pharmacol. 13:1075966.
doi: 10.3389/fphar.2022.1075966

COPYRIGHT

© 2022 Guo, Wang, Yuan, Wu, Liu, He
and Wang. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system

Haoning Guo¹, Bin Wang², Shuying Yuan¹, Silin Wu¹, Jing Liu^{3*},
Miaoquan He^{1*} and Jisheng Wang^{1*}

¹Division of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China, ²Clinical Experimental Center, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China, ³Department of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China

KEYWORDS

esketamine, pharmacovigilance, neurological adverse events, signal, FAERS, disproportionality analysis

A Corrigendum on Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system

by Guo H, Wang B, Yuan S, Wu S, Liu J, He M and Wang J (2022). *Front. Pharmacol.* 13:849758.
doi: 10.3389/fphar.2022.849758

In the original article, there was an error in affiliation 1. Instead of “Division of Psychopharmacology, Department of Pharmacy, The Third People’s Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”, it should be “Division of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”. In the published article, there was an error in affiliation 3. Instead of “Department of Pathology, The Third People’s Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”, it should be “Department of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.